 Collaboration to evaluate NEObodyTM product candidate, ADG106, in combination with KEYTRUDA for patients with advanced or metastatic solid andor hematological malignancies Collaboration to evaluate NEObodyTM product candidate, ADG106, in combination with KEYTRUDA for patients with advanced or metastatic solid andor hematological malignancies 